973 related articles for article (PubMed ID: 24429703)
1. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
Nat Commun; 2014; 5():2997. PubMed ID: 24429703
[TBL] [Abstract][Full Text] [Related]
2. Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine.
Röcken C; Amallraja A; Halske C; Opasic L; Traulsen A; Behrens HM; Krüger S; Liu A; Haag J; Egberts JH; Rosenstiel P; Meißner T
Genome Med; 2021 Nov; 13(1):177. PubMed ID: 34749812
[TBL] [Abstract][Full Text] [Related]
3. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.
Dentro SC; Leshchiner I; Haase K; Tarabichi M; Wintersinger J; Deshwar AG; Yu K; Rubanova Y; Macintyre G; Demeulemeester J; Vázquez-García I; Kleinheinz K; Livitz DG; Malikic S; Donmez N; Sengupta S; Anur P; Jolly C; Cmero M; Rosebrock D; Schumacher SE; Fan Y; Fittall M; Drews RM; Yao X; Watkins TBK; Lee J; Schlesner M; Zhu H; Adams DJ; McGranahan N; Swanton C; Getz G; Boutros PC; Imielinski M; Beroukhim R; Sahinalp SC; Ji Y; Peifer M; Martincorena I; Markowetz F; Mustonen V; Yuan K; Gerstung M; Spellman PT; Wang W; Morris QD; Wedge DC; Van Loo P;
Cell; 2021 Apr; 184(8):2239-2254.e39. PubMed ID: 33831375
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.
Croucher DC; Richards LM; Tsofack SP; Waller D; Li Z; Wei EN; Huang XF; Chesi M; Bergsagel PL; Sebag M; Pugh TJ; Trudel S
Nat Commun; 2021 Nov; 12(1):6322. PubMed ID: 34732728
[TBL] [Abstract][Full Text] [Related]
5. The genetic landscape of 5T models for multiple myeloma.
Maes K; Boeckx B; Vlummens P; De Veirman K; Menu E; Vanderkerken K; Lambrechts D; De Bruyne E
Sci Rep; 2018 Oct; 8(1):15030. PubMed ID: 30301958
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.
Zheng B; Yi K; Zhang Y; Pang T; Zhou J; He J; Lan H; Xian H; Li R
Clin Exp Med; 2023 Nov; 23(7):3833-3846. PubMed ID: 37515690
[TBL] [Abstract][Full Text] [Related]
7. Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
Maura F; Bolli N; Angelopoulos N; Dawson KJ; Leongamornlert D; Martincorena I; Mitchell TJ; Fullam A; Gonzalez S; Szalat R; Abascal F; Rodriguez-Martin B; Samur MK; Glodzik D; Roncador M; Fulciniti M; Tai YT; Minvielle S; Magrangeas F; Moreau P; Corradini P; Anderson KC; Tubio JMC; Wedge DC; Gerstung M; Avet-Loiseau H; Munshi N; Campbell PJ
Nat Commun; 2019 Aug; 10(1):3835. PubMed ID: 31444325
[TBL] [Abstract][Full Text] [Related]
8. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.
Baughn LB; Jessen E; Sharma N; Tang H; Smadbeck JB; Long MD; Pearce K; Smith M; Dasari S; Sachs Z; Linden MA; Cook J; Keith Stewart A; Chesi M; Mitra A; Leif Bergsagel P; Van Ness B; Kumar SK
Blood Cancer J; 2023 May; 13(1):84. PubMed ID: 37217482
[TBL] [Abstract][Full Text] [Related]
9. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Poos AM; Prokoph N; Przybilla MJ; Mallm JP; Steiger S; Seufert I; John L; Tirier SM; Bauer K; Baumann A; Rohleder J; Munawar U; Rasche L; Kortüm KM; Giesen N; Reichert P; Huhn S; Müller-Tidow C; Goldschmidt H; Stegle O; Raab MS; Rippe K; Weinhold N
Blood; 2023 Nov; 142(19):1633-1646. PubMed ID: 37390336
[TBL] [Abstract][Full Text] [Related]
10. Correlation of changes in subclonal architecture with progression in the MMRF CoMMpass study.
Kaur G; Jena L; Gupta R; Farswan A; Gupta A; Sriram K
Transl Oncol; 2022 Sep; 23():101472. PubMed ID: 35777247
[TBL] [Abstract][Full Text] [Related]
11. RAS/RAFlandscape in monoclonal plasma cell conditions.
Schavgoulidze A; Corre J; Samur MK; Mazzotti C; Pavageau L; Perrot A; Cazaubiel T; Leleu X; Macro M; Belhadj K; Roussel M; Brechignac S; Montes L; Caillot D; Frenzel L; Rey P; Schiano JM; Chalopin T; Jacquet C; Richez V; Orsini Piocelle F; Fontan J; Manier S; Martinet L; Sciambi A; Mohty M; Avet-Loiseau H
Blood; 2024 Apr; ():. PubMed ID: 38643494
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic aberrations in the pathogenesis of multiple myeloma.
Bong IPN; Esa E
Asian Biomed (Res Rev News); 2023 Aug; 17(4):152-162. PubMed ID: 37860676
[TBL] [Abstract][Full Text] [Related]
13. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G; Cibulskis K; McKenna A; Chapman MA; Straussman R; Levy J; Perkins LM; Keats JJ; Schumacher SE; Rosenberg M; ; Getz G; Golub TR
Cancer Cell; 2014 Jan; 25(1):91-101. PubMed ID: 24434212
[TBL] [Abstract][Full Text] [Related]
14. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
15. Genomic complexity of multiple myeloma and its clinical implications.
Manier S; Salem KZ; Park J; Landau DA; Getz G; Ghobrial IM
Nat Rev Clin Oncol; 2017 Feb; 14(2):100-113. PubMed ID: 27531699
[TBL] [Abstract][Full Text] [Related]
16. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
[TBL] [Abstract][Full Text] [Related]
17. Differential and limited expression of mutant alleles in multiple myeloma.
Rashid NU; Sperling AS; Bolli N; Wedge DC; Van Loo P; Tai YT; Shammas MA; Fulciniti M; Samur MK; Richardson PG; Magrangeas F; Minvielle S; Futreal PA; Anderson KC; Avet-Loiseau H; Campbell PJ; Parmigiani G; Munshi NC
Blood; 2014 Nov; 124(20):3110-7. PubMed ID: 25237203
[TBL] [Abstract][Full Text] [Related]
18. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
[TBL] [Abstract][Full Text] [Related]
19. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
